# Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

> **NCT04940026** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer
- Healthy Volunteers

## Interventions

- **DRUG:** amcenestrant
- **DRUG:** [14C]-SAR439859 microtracer
- **DRUG:** [14C]-SAR439859

## Key facts

- **NCT ID:** NCT04940026
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2021-08-19
- **Final completion:** 2021-08-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04940026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04940026, "Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04940026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*